What is Piramal Pharma Ltd. Quarterly Revenue?

Piramal Pharma Ltd. Quarterly Revenue Piramal Pharma Sep-2026 Quarterly Revenue is Rs 1,483 Cr which is growth of 11.6% YoY.

What is Piramal Pharma Ltd. Quarterly Net Profit?

Piramal Pharma Ltd. Quarterly Net Profit Piramal Pharma Sep-2026 Quarterly Net Profit is Rs 171 Cr which is growth of -13.0% YoY.

What is Piramal Pharma Ltd. Annual Revenue?

Piramal Pharma Ltd. Annual Revenue Piramal Pharma Mar-2026 Annual Revenue is Rs 5,445 Cr which is growth of -0.9% YoY.

What is Piramal Pharma Ltd. Annual Net Profit?

Piramal Pharma Ltd. Annual Net Profit Piramal Pharma Mar-2026 Annual Net Profit is Rs 700 Cr which is growth of 1.2% YoY.

What is Piramal Pharma Ltd. Total Shareholders Fund?

Piramal Pharma Ltd. Total Shareholders Fund Piramal Pharma Mar-2026 Total Shareholders Fund is Rs 8,141 Cr which is growth of 9.2% YoY.

What is Piramal Pharma Ltd. Total Assets?

Piramal Pharma Ltd. Total Assets Piramal Pharma Mar-2026 Total Assets is Rs 11,753 Cr which is growth of 13.1% YoY.

What is Piramal Pharma Ltd. Book Value Per Share?

Piramal Pharma Ltd. Book Value Per Share Piramal Pharma Mar-2026 Book Value Per Share is 61 Rs which is growth of 9.0% YoY.

What is Piramal Pharma Ltd. ROE?

Piramal Pharma Ltd. ROE Piramal Pharma Mar-2026 ROE is 9% which is growth of 0.7% YoY.

What is Piramal Pharma Ltd. Cash From Operating Activity?

Piramal Pharma Ltd. Cash From Operating Activity Piramal Pharma Mar-2026 Cash From Operating Activity is Rs 1,328 Cr which is growth of 142.0% YoY.

What is Piramal Pharma Ltd. Net Cash Flow?

Piramal Pharma Ltd. Net Cash Flow Piramal Pharma Mar-2026 Net Cash Flow is Rs 395 Cr which is growth of 727.7% YoY.

Piramal Pharma Ltd.

NSE: PPLPHARMA | BSE: 543635

Expensive Rocket

Download real time

US FDA Inspections ANDA Approvals

-0.53(-0.22%)

New 52W High in past week

3.2M

NSE+BSE Volume

NSE 13 Nov, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Piramal Pharma quarterly and annual financials: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Piramal Pharma share price target, revenues, EPS, net income and more

Piramal Pharma quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

Nested row level

Base Level

Export

POSITIVE
Quarterly Revenue Piramal Pharma Sep-2026 Quarterly Revenue is Rs 1,483 Cr which is growth of 11.6% YoY.
NEGATIVE
Quarterly Net Profit Piramal Pharma Sep-2026 Quarterly Net Profit is Rs 171 Cr which is growth of -13.0% YoY.

Piramal Pharma Ltd., Quarterly, standalone, All financials are in INR Cr and price data in INR
Indicator	Sep '26	Jun '26	Mar '26	Dec '25	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24	Mar '24	Dec '23	Sep '23
TOTAL_SR_Q Total Rev. ⌄	1,483.3	1,239.6	1,672.8	1,292	1,329.2	1,150.8	1,729.3	1,273	1,390.8	1,100	1,578.5	1,057.3	1,083.3
SR_Q Operating Rev.	1,345.4	1,125	1,489.1	1,195.8	1,127.3	969.9	1,689.8	1,248.3	1,284.4	1,063.2	1,525.3	1,024.1	994.2
OI_Q Other Income	137.9	114.6	183.7	96.2	202	180.9	39.5	24.7	106.4	36.8	53.2	33.1	89.1
OEXPNS_Q Operating Exp.	1,173.9	1,008	1,185.7	1,028.6	1,000.2	925.6	1,273.2	1,029	1,031.5	911.6	1,135.7	898.6	908.1
OEXPNS_Q Operating Exp.	1,173.9	1,008	1,185.7	1,028.6	1,000.2	925.6	1,273.2	1,029	1,031.5	911.6	1,135.7	898.6	908.1
OP_Q Operating Profit	171.5	116.9	303.4	167.3	127.1	44.3	416.6	219.3	252.9	151.6	389.6	125.5	86.2
OPMPCT_Q Operating Profit Margin %	12.75%	10.40%	20.37%	13.99%	11.27%	4.57%	24.65%	17.57%	19.69%	14.26%	25.55%	12.26%	8.67%
DEP_Q Depr.	67.6	65.7	70.1	64.7	61.3	59.4	61.2	55.5	53.6	51.9	52.5	51.6	50.8
INT_Q Interest	17.3	16.4	19.5	16.8	20.4	23.2	30.6	29.2	30	24.9	27.7	17.4	28.2
PBT_Q Profit Before Tax	224.6	149.5	331.9	154.9	247.4	142.6	364.4	159.4	275.7	111.7	362.7	89.7	96.2
TAX_Q Tax	53.9	36	70.2	26	51.1	29.4	87.1	40.6	65.7	26.4	89.6	15.3	19
NP_Q Net Profit	170.7	113.5	261.6	128.9	196.3	113.1	277.3	118.8	210.1	85.3	273.1	74.3	77.2
EPS_adj_Q EPS Adj. latest	1.3	0.9	2	1	1.5	0.9	2.1	0.9	1.6	0.6	2.1	0.6	0.6
NP_TTM Net profit TTM	674.8	700.4	700	715.7	705.5	719.3	691.4	687.2	642.8	509.9	391.2	159.8	83.1
EPS_TTM Basic EPS TTM	5.1	5.3	5.3	5.4	5.3	5.4	5.2	5.2	4.9	3.9	3	1.2	0.6
earnings_transcripts Earnings Transcripts
results_pdf Results PDF
result_notes Result Notes	Notes	Notes	Notes	Notes	Notes	Notes		Notes	Notes	Notes	Notes	Notes

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

Piramal Pharma competitor comparison and performance snapshot within industry

Piramal Pharma annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEGATIVE
Annual Revenue Piramal Pharma Mar-2026 Annual Revenue is Rs 5,445 Cr which is growth of -0.9% YoY.
POSITIVE
Annual Net Profit Piramal Pharma Mar-2026 Annual Net Profit is Rs 700 Cr which is growth of 1.2% YoY.

Piramal Pharma Ltd., Annual, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	TTM	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21
SR_A Total Rev. Ann. ⌄	12.9%	11.7%	5,687.6	5,444.7	5,493.1	4,592.2	3,784.3	3,318.5	3,136.8
TotalOperatingRevenues_A Operating Rev. Ann.	11.6%	10.2%	5,155.2	4,782	5,285.7	4,390.1	3,443.2	3,095	2,938.8
OI_A Other Income Ann.	24.8%	27.3%	532.4	662.7	207.4	202.1	341.1	223.6	198
OEXPNS_A Operating Exp. Ann.	7.4%	12.3%	4,396.2	4,140	4,245.3	3,772.2	3,345.7	2,697.7	2,319.9
OEXPNS_A Operating Exp. Ann.	7.4%	12.3%	4,396.2	4,140	4,245.3	3,772.2	3,345.7	2,697.7	2,319.9
OP_A Operating Profit Ann.	87.4%	0.7%	759	642	1,040.4	617.9	97.5	397.3	618.9
OPMPCT_A OPM Ann. %	65.9%	-9.8%		11.79%	18.94%	13.46%	2.58%	11.97%	19.73%
TotalExpenses_A Total Exp. Ann. ⌄	7%	12.6%		4,475.5	4,581.9	4,084.6	3,653.6	2,881.8	2,468.2
OtherExpenses_A Other Exp. Ann.	8.8%	13.7%	1,321.4	1,325.3	1,263.1	1,049.4	1,028.7	789.1	697
EmployeeBenefitExpenses_A Employee Exp. Ann.	10.7%	13.5%	788.9	744.8	736.2	613.9	548.5	425.3	395.2
CostOfPowerPurchased_A Cost Of Power Purchased Ann.	-	-
CostOfFuel_A Cost Of Fuel Ann.	-	-
EBIDT_A EBITDA Ann.	43.8%	9.8%		1,304.7	1,247.8	820	438.6	620.9	816.9
EBIDTPCT_A EBITDA Ann. margin %	27.4%	-1.7%		23.96%	22.72%	17.86%	11.59%	18.71%	26.04%
INT_A Interest Ann.	-11.6%	76.3%	70	80	114.6	107.1	115.9	53.6	4.7
DEP_A Depr.	10%	12.2%	268.1	255.5	222.1	205.3	192.1	130.6	143.6
PBT_A PBT Ann.	92.1%	5%	860.9	876.8	911.1	507.6	123.7	424.2	686.8
TAX_A Tax Ann.	48.3%	8.9%	186.1	176.8	219.7	116.4	54.2	81.2	115.3
PAT_A PAT Before ExtraOrdinary Items Ann. ⌄	116%	4.1%		700	691.4	391.2	69.5	343.1	571.5
IncomeMinorityInterest_A Minority Interest Income Ann.	-	-		-	-	-	-	-	-
NP_A Net Profit Ann.	116%	4.1%	674.8	700	691.4	391.2	69.5	343.1	571.5
NETPCT_A NPM Ann. %	93.8%	-5.5%		14.63%	13.08%	8.91%	2.01%	11.08%	19.44%
EPS_adj_A EPS Adj. latest Ann.	119.7%	4.3%		5.3	5.2	2.9	0.5	2.6	4.3
result_notes Result Notes				Notes		Notes	Notes
Annual_Reports Annual Reports

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

Total Rev. Ann.

1Y CHG

-0.9%

2Y CAGR

8.9%

3Y CAGR

12.9%

5Y CAGR

11.7%

Total Revenue Annual is falling faster than historical averages.

Net Profit Ann.

1Y CHG

1.2%

2Y CAGR

33.8%

3Y CAGR

116%

5Y CAGR

4.1%

Net Profit Annual growth is lower than historical averages.

Operating Exp. Ann.

1Y CHG

-2.5%

2Y CAGR

4.8%

3Y CAGR

7.4%

5Y CAGR

12.3%

Operating Expenses Annual Cr is falling faster than historical averages.

Piramal Pharma balance sheet as of Mar 2026: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Total Shareholders Fund Piramal Pharma Mar-2026 Total Shareholders Fund is Rs 8,141 Cr which is growth of 9.2% YoY.
POSITIVE
Total Assets Piramal Pharma Mar-2026 Total Assets is Rs 11,753 Cr which is growth of 13.1% YoY.

Piramal Pharma Ltd., Balance Sheet, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21
TotalShareHoldersFunds_A Total ShareHolders Funds Ann. ⌄	15.7%	14.7%	8,141.1	7,452.5	6,712.1	5,261.8	5,067.3	4,100.6
EQCAP_A Equity Share Capital Ann.	3.6%	5.9%	1,327.2	1,324.4	1,323	1,193.3	1,185.9	994.6
TotalShareCapital_A Total Share Capital Ann.	3.6%	5.9%	1,327.2	1,324.4	1,323	1,193.3	1,185.9	994.6
ReservesAndSurplus_A Reserves Plus Surplus Ann.	18.8%	17%	6,814	6,128.2	5,389.1	4,068.5	3,881.4	3,105.9
TotalReservesAndSurplus_A Total Reserves Plus Surplus Ann.	18.8%	17%	6,814	6,128.2	5,389.1	4,068.5	3,881.4	3,105.9
LiabilityMinorityInterest_A Minority Interest Liability Ann.	-	-	-	-	-	-	-	-
TotalNonCurrentLiabilities_A Total Non Current Liabilities Ann. ⌄	0.7%	35.6%	845.9	632.8	611	829.3	623.8	184.4
DeferredTaxLiabilities_A Deferred Tax Liabilities Ann.	11.5%	9.6%	269.3	213.1	196.6	194.2	157.5	170.4
OtherLongTermLiabilities_A Other LongTerm Liabilities Ann.	40.2%	52.7%	61.4	14.3	18.2	22.3	8	7.4
CL_A Total Current Liabilities Ann. ⌄	12.3%	13.5%	2,766.3	2,306.5	2,227.8	1,951.3	1,517.1	1,471.7
TradePayables_A Trade Payables Ann.	38.2%	28.1%	2,011.5	1,184.8	1,107.7	761.7	615.2	584.1
OtherCurrentLiabilities_A Other Current Liabilities Ann.	54.2%	-9.3%	423.6	213.8	288.6	115.5	215.5	691.5
ShortTermProvisions_A ST Provisions Ann.	2.5%	6.4%	42.2	42.9	43.6	39.2	32.5	30.9
TL_A Total Capital Plus Liabilities Ann.	13.5%	15.3%	11,753.3	10,391.8	9,550.9	8,042.4	7,208.3	5,756.7
FixedAssets_A Fixed Assets Ann. ⌄	2.6%	13.3%	3,257	3,221.6	3,145.4	3,018.4	1,814.1	1,747.8
TangibleAssets_A Tangible Assets Ann.	6.8%	10.9%	2,188	2,128.8	1,850.6	1,796.1	1,310	1,305.2
IntangibleAssets_A Intangible Assets Ann.	1.7%	21.4%	847.9	765.5	761.6	805.8	299	321.6
CapitalWorkInProgress_A Capital Work In Progress Ann.	-9.4%	5.1%	101.5	77.7	232.4	136.5	155.3	79.3
TotalNonCurrentAssets_A Total Non Current Assets Ann. ⌄	8.9%	13%	7,355.2	6,856	6,259.3	5,693.7	5,249.8	3,989.2
NonCurrentInvestments_A Non Current Investments Ann.	28.4%	17%	3,486.1	3,105.3	1,646.9	1,646.9	2,597.3	1,591.5
DeferredTaxAssets_A Deferred Tax Assets Ann.	-	-
LongTermLoansAndAdvances_A LT Loans Plus Advances Ann.	-19.2%	-3.6%	511.5	456.6	1,395.2	970.7	791.7	613.8
OtherNonCurrentAssets_A Other Non Current Assets Ann.	20.3%	22.8%	100.6	72.5	71.9	57.8	46.8	36
CA_A Total Current Assets Ann. ⌄	23.3%	20%	4,398.1	3,535.9	3,291.6	2,348.7	1,958.5	1,767.5
CurrentInvestments_A Current Investments Ann.	-2.2%	-	93.6		61.3	100.1	37
TradeReceivables_A Trade Receivables Ann.	15.6%	10.9%	1,405.8	1,666.7	1,331.4	909.6	947.7	839.8
CashAndCashEquivalents_A Cash Plus Cash Equivalents Ann.	107.6%	30.4%	574.3	177.8	241.7	64.2	90.3	152.4
ShortTermLoansAndAdvances_A ST Loans Plus Advances Ann.	-12.7%	16.5%	22.7	12.5	47.2	34.1	47.3	10.6
OtherCurrentAssets_A Other Current Assets Ann.	0.5%	4.5%	428.3	473.5	456.9	422.1	355	343.9
TA_A Total Assets Ann.	13.5%	15.3%	11,753.3	10,391.8	9,550.9	8,042.4	7,208.3	5,756.7
ContingentLiabilities_A Contingent Liabilities plus Commitments Ann.	41.9%	41.7%	430.2	200.7	190.3	150.7	102	75.2
BonusEquityShareCapital_A Bonus Equity Share Capital Ann.	0%	-	177.7	177.7	177.7	177.7	177.7
NonCurrentInvestmentsUnquotedBookValue_A Non Current Investments Unquoted Book Value Ann.	28.4%	17%	3,486	3,105.3	1,646.9	1,646.8	2,597.3	1,591.5
CurrentInvestmentsUnquotedBookValue_A Current Investments Unquoted Book Value Ann.	-	-					37

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

Total Assets Ann.

1Y CHG

13.1%

2Y CAGR

10.9%

3Y CAGR

13.5%

5Y CAGR

15.3%

Total Assets Annual growth is lower than historical averages.

Total Current Liabilities Ann.

1Y CHG

19.9%

2Y CAGR

11.4%

3Y CAGR

12.3%

5Y CAGR

13.5%

Total Current Liabilities Annual Cr growth is higher than historical averages.

Total ShareHolders Funds Ann.

1Y CHG

9.2%

2Y CAGR

10.1%

3Y CAGR

15.7%

5Y CAGR

14.7%

Total ShareHolders Funds Annual growth is lower than historical averages.

Piramal Pharma ROE, ROCE, book value, and debt-to-equity ratio as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Book Value Per Share Piramal Pharma Mar-2026 Book Value Per Share is 61 Rs which is growth of 9.0% YoY.
POSITIVE
ROE Piramal Pharma Mar-2026 ROE is 9% which is growth of 0.7% YoY.

Piramal Pharma Ltd., Ratios, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21
BVSH_A BVSH Ann.	11.6%	8.3%	61.3	56.3	50.7	44.1	42.7	41.2
ROA_A RoA Ann. %	90.5%	-9.7%	5.95%	6.65%	4.09%	0.86%	4.75%	9.92%
ROE_A ROE Ann. %	86.7%	-9.2%	8.59%	9.27%	5.82%	1.32%	6.76%	13.93%
ROCE_A ROCE Ann. %	42.4%	-5.8%	11.67%	12.68%	8.39%	4.04%	8.61%	15.71%
ProfitabilityHeader Profitability Ratio ⌄
PBDITMargin_A EBITDA Ann. Margin %	28.9%	-0.4%	27.28%	23.60%	18.67%	12.73%	20.06%	27.79%
PBITMargin_A EBIT Ann. Margin %	45.3%	-0.9%	21.94%	19.40%	14.00%	7.15%	15.84%	22.90%
PBTMargin_A PBT Ann. Margin %	72.2%	-4.7%	18.33%	17.23%	11.56%	3.59%	13.70%	23.36%
NETPCT_A NPM Ann. %	93.8%	-5.5%	14.63%	13.08%	8.91%	2.01%	11.08%	19.44%
ASETTO_A Asset Turnover Ann. %	-7.2%	-	0.4	0.5	0.5	0.5	0.5	-
LiquidityHeader Liquidity Ratio ⌄
CRATIO_A Current Ratio Ann.	10.1%	5.9%	1.6	1.5	1.5	1.2	1.3	1.2
QuickRatio_A Quick Ratio Ann.	4%	0%	0.9	1	1	0.8	1	0.9
DividendPayoutNP_A Dividend Payout to NP Ann.	-	-	0	0				-
EarningRetention_A Earning Retention Ann. %	-	-	97.36%	97.91%
CashEarningRetention_A Cash Earning Retention Ann. %	-	-	98.06%	98.42%
CashEarningRetention_A Cash Earning Retention Ann. %	-	-	98.06%	98.42%
ValuationHeader Valuation Ratio ⌄
EnterpriseValue_A EnterpriseValue Ann.	23.3%	-	18,244.7	30,775.8	17,963	9,729
EVPerNetSales_A EV Per Net Sales Ann.	10.7%	-	3.8	5.8	4.1	2.8	-	-
PBV_A Price To Book Value Adjusted	-10.3%	-7.6%	4	4.63	4.82	5.55	5.72	5.93
EVPerEBITDA_A EV Per EBITDA Ann.	-14.2%	-	14	24.7	21.9	22.2	-	-
MarketCapPerSales_A Market Cap Per Sales Ann.	16.6%	-	3.8	5.6	3.9	2.4	-	-
RetentionRatios_A Retention Ratio Ann. %	-	-	97.35%	97.90%
EYield_A Earnings Yield Ann.	-	-	0	0	0	0
DEBT_CE_A Total Debt to Total Equity Ann.	-30.7%	-	0.1	0.2	0.2	0.3	0.2	0

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

ROE Ann. %

1Y CHG

-7.3%

2Y CAGR

21.5%

3Y CAGR

86.7%

5Y CAGR

-9.2%

ROE Annual % is falling faster than historical averages.

RoA Ann. %

1Y CHG

-10.5%

2Y CAGR

20.6%

3Y CAGR

90.5%

5Y CAGR

-9.7%

RoA Annual % is falling faster than historical averages.

Current Ratio Ann.

1Y CHG

6.7%

2Y CAGR

3.3%

3Y CAGR

10.1%

5Y CAGR

5.9%

Current Ratio Annual growth is lower than historical averages.

Piramal Pharma cash flow: net, operating, investing, and financing flows as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Cash From Operating Activity Piramal Pharma Mar-2026 Cash From Operating Activity is Rs 1,328 Cr which is growth of 142.0% YoY.
POSITIVE
Net Cash Flow Piramal Pharma Mar-2026 Net Cash Flow is Rs 395 Cr which is growth of 727.7% YoY.

Piramal Pharma Ltd., Cash Flow, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21
CFO_A Cash from Operating Act. Ann. ⌄	164.8%	107.3%	1,328.1	548.8	358.3	71.5	255.2	34.7
PBT_A PBT Ann.	92.1%	5%	876.8	911.1	507.6	123.7	424.2	686.8
INT_A Interest Ann.	-11.6%	76.3%	80	114.6	107.1	115.9	53.6	4.7
TAX_A Tax Ann.	48.3%	8.9%	176.8	219.7	116.4	54.2	81.2	115.3
CFI_A Cash from Investing Act. Ann.	-	-	-317.8	-550	-635.5	-435.1	-1,223	-4,382.9
CFA_A Cash from Financing Act. Ann.	-	-	-615.1	-61.7	451.4	290.1	905.7	4,494.2
NCF_A Net Cash Flow Ann. ⌄	-	22%	395.2	-63	174.2	-73.4	-62.1	146
CashAndCashEquivalentBeginOfYear_A Cash Plus Cash Eqv. Begin Of Year Ann.	8.7%	197.8%	163.9	228.8	54.3	127.7	146.7	0.7
CashAndCashEquivalentEndOfYear_A Cash Plus Cash Eqv. End Of Year Ann.	117.5%	30.7%	559	163.9	228.8	54.3	84.7	146.7

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

Cash from Operating Act. Ann.

1Y CHG

142%

2Y CAGR

92.5%

3Y CAGR

164.8%

5Y CAGR

107.3%

Cash from Operating Activity Annual growth is stable compared to historical averages.

Piramal Pharma investor presentations, annual reports, credit ratings, and earnings calls with AI summary, video, and audio access

Forecaster
Quarterly
Competitors/Peers
Annual
Balance Sheet
Ratios
Cash Flow
Documents

Piramal Pharma quarterly and annual financials: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

Piramal Pharma - Forecaster

Forecaster Analyst Estimates for Piramal Pharma share price target, revenues, EPS, net income and more